Literature DB >> 27997042

What do we know about the inflammasome in humans?

Jay Amin1,2, Delphine Boche1, Sonja Rakic1.   

Abstract

The inflammasome complex is part of the innate immune system, which serves to protect the host against harm from pathogens and damaged cells. It is a term first proposed by Tschopp's group in 2002, with numerous original research articles and reviews published on the topic since. There have been many types of inflammasome identified, but all result in the common pathway of activation of caspases and interleukin 1β along with possible cell death called pyroptosis. Despite a growing body of research investigating the structure and function of the inflammasome in animal models, there is still limited evidence identifying inflammasome components in human physiology and disease. In this review, we explore the molecular structure and mechanism of activation of the inflammasome with a particular focus on inflammasome complexes expressed in humans. Inflammasome components have been identified in several human peripheral and brain tissues using both in vivo and ex vivo work, and the inflammasome complex has been shown to be associated with several genetic and acquired inflammatory and neoplastic disorders. We discuss the strengths and weaknesses of the information available on the inflammasome with an emphasis on the importance of prioritizing work on human tissue. There is a huge demand for more effective treatments for a number of inflammatory and neurodegenerative diseases. Modulation of the inflammasome has been proposed as a novel treatment for several of these diseases and there are currently clinical trials ongoing to test this theory.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  NLRP; human; inflammasome; inflammasomopathies; inflammation; innate immunity

Mesh:

Substances:

Year:  2017        PMID: 27997042     DOI: 10.1111/bpa.12479

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  12 in total

1.  Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.

Authors:  Binit Kumar; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2018-03-19       Impact factor: 11.454

Review 2.  A Spotlight on the Underlying Activation Mechanisms of the NLRP3 Inflammasome and its Role in Atherosclerosis: A Review.

Authors:  Anam Liaqat; Muhammad Asad; Fatima Shoukat; Arif-Ullah Khan
Journal:  Inflammation       Date:  2020-12       Impact factor: 4.092

Review 3.  NLRP3: A Novel Mediator in Cardiovascular Disease.

Authors:  Wenyi Zhou; Chunyuan Chen; Zhiheng Chen; Lin Liu; Jie Jiang; Zhixiang Wu; Mingyi Zhao; Yanfang Chen
Journal:  J Immunol Res       Date:  2018-04-08       Impact factor: 4.818

4.  The inflammasome in leprosy skin lesions: an immunohistochemical evaluation.

Authors:  Luciana Mota Silva; Jorge Rodrigues de Sousa; Kelly Emi Hirai; Leônidas Braga Dias; Ismari Perini Furlaneto; Francisca Regina Oliveira Carneiro; Tinara Leila de Souza Aarão; Mirian Nacagami Sotto; Juarez Antonio Simões Quaresma
Journal:  Infect Drug Resist       Date:  2018-11-12       Impact factor: 4.003

5.  IFN Regulatory Factor 1 Mediates Macrophage Pyroptosis Induced by Oxidized Low-Density Lipoprotein in Patients with Acute Coronary Syndrome.

Authors:  Min Guo; Rui Yan; Hongmei Yao; Liqin Duan; Meng Sun; Zheng Xue; Yongping Jia
Journal:  Mediators Inflamm       Date:  2019-12-01       Impact factor: 4.711

Review 6.  Role of NLRP3 Inflammasome Activation in Obesity-Mediated Metabolic Disorders.

Authors:  Kaiser Wani; Hind AlHarthi; Amani Alghamdi; Shaun Sabico; Nasser M Al-Daghri
Journal:  Int J Environ Res Public Health       Date:  2021-01-10       Impact factor: 3.390

7.  Fluoxetine-enhanced autophagy ameliorates early brain injury via inhibition of NLRP3 inflammasome activation following subrachnoid hemorrhage in rats.

Authors:  Jian-Ru Li; Hang-Zhe Xu; Sheng Nie; Yu-Cong Peng; Lin-Feng Fan; Zhi-Jiang Wang; Cheng Wu; Feng Yan; Jing-Yin Chen; Chi Gu; Chun Wang; Jing-Sen Chen; Lin Wang; Gao Chen
Journal:  J Neuroinflammation       Date:  2017-09-13       Impact factor: 8.322

Review 8.  Potential immunotherapies for traumatic brain and spinal cord injury.

Authors:  Raj Putatunda; John R Bethea; Wen-Hui Hu
Journal:  Chin J Traumatol       Date:  2018-04-18

Review 9.  Nutraceutical Compounds Targeting Inflammasomes in Human Diseases.

Authors:  Beatriz Castejón-Vega; Francesca Giampieri; José M Alvarez-Suarez
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

Review 10.  Inflammation and Inflammasomes: Pros and Cons in Tumorigenesis.

Authors:  Liliana R Balahura; Aida Selaru; Sorina Dinescu; Marieta Costache
Journal:  J Immunol Res       Date:  2020-09-19       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.